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ABSTRACT 
    Bone morphogenetic proteins (BMPs) are 
secreted growth factors that promote 
differentiation processes in embryogenesis and 
tissue development. Regulation of BMP 
signalling involves binding to a variety of 
extracellular proteins, among which are many 
von Willebrand factor C (vWC) domain-
containing proteins. While the crystal structure 
of the complex of crossveinless-2 (CV-2) vWC1 
and BMP-2 previously revealed one mode of the 
vWC:BMP binding mechanism, other vWC 
domains may bind to BMP differently. Here, 
using X-ray crystallography, we present for the 
first time  structures of the vWC domains of two 
proteins thought to interact with BMP-2—
collagen IIA and matricellular protein CCN3. 
We found that these two vWC domains share a 
similar N-terminal fold that differs greatly from 
that in CV-2 vWC, which comprises its BMP-2-
binding site. We analysed the ability of these 
vWC domains to directly bind to BMP-2 
and detected an interaction only between the 
collagen IIa vWC and BMP-2. Guided by the 
collagen IIa vWC domain crystal structure and 
conservation of surface residues among 
orthologous domains, we mapped the BMP-
binding epitope on the subdomain 1 of the vWC 
domain. This binding site is different from that 
previously observed in the complex between CV-
2 vWC and BMP-2, revealing an alternative 
mode of interaction between vWC domains and 
BMPs.  
 
    Bone morphogenetic proteins (BMPs) are 
members of the TGF-β superfamily, a group of 
extracellular growth factors that play important 
roles in embryonic patterning, differentiation, and 
homeostasis of various tissue types (1). Many 
biological processes rely on the normal functioning 
of BMPs, including the development and 
maintenance of cartilage and bones, wound repair, 
and tissue homeostasis, whereas perturbations of 
BMP signalling are implicated in diseased states 
such as fibrosis, vascular diseases, and cancer 
progression (2–8). Secreted dimeric BMPs signal 
these processes through binding of two type I and 
two type II serine/threonine kinase receptors, which 
in turn phosphorylate Smad 1/5/8 proteins and 
MAP kinases to ultimately regulate gene expression 
(9). Furthermore, the regulation of BMP signalling 
involves direct binding by a range of extracellular 
proteins, including Follistatin, Gremlins, and 
Noggin, that inhibit the receptor-mediated activity 
of BMPs (10–15). 
    Many regulatory proteins, such as the Chordin 
family members Crossveinless-2 (CV-2), Chordin, 
and Chordin-like 2 (CHL2), bind BMPs through 
von Willebrand factor C (vWC) domains. The vWC 
domain, originally identified in the von Willebrand 
factor (16), typically contains 75-100 residues, with 
ten conserved cysteines. Two cysteine-containing 
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motifs, CXXCXC and CCXXC, lie toward the 
middle and the C-terminal parts of the domain, 
respectively (17). X-ray crystallographic and NMR 
structures have revealed that vWC domains 
comprise an N-terminal region, and two 
subdomains of SD1 and SD2 linked together by a 
disulfide bond (17, 18). CV-2, Chordin, and CHL2 
each contain multiple vWC domains that interact 
with BMPs with variable affinities (18–22). 
Moreover, the various vWC domains have been 
shown to interact with either or both of the types I 
and II receptor binding sites on BMP-2, thereby 
resulting in different mechanisms of inhibition of 
BMP signalling (18, 21, 22).  
    The crystal structure of the first vWC domain of 
CV-2 (CV-2 vWC1) in complex with BMP-2 
revealed one modality of the vWC:BMP-2 
interaction (18). The CV-2 vWC1 binds to BMP-2 
through two separate sites of interactions. Firstly, 
there is high-affinity binding between its N-
terminal clip and the type I receptor binding site on 
BMP-2 via hydrogen bonds, at a nanomolar affinity 
compatible with the type I receptor:BMP-2 
interaction. As shown by its NMR structure in 
solution at unbound state, this BMP-2 compatible  
conformation of the N-terminal clip is pre-formed 
in the CV-2 vWC domain instead of being induced 
by complexation (23), suggesting that the N-
terminal structure of a vWC domain could be 
indicative of its binding mechanism with BMPs. 
Secondly, there are hydrophobic interactions 
between its SD1 and the type II receptor binding 
site on BMP-2 at a similarly low affinity. The SD2 
of CV-2 vWC1 was shown to make no contact with 
BMP-2 (18). For other BMP-binding vWC domains 
in Chordin and CHL2, the BMP2-binding epitopes 
have also been pinned down in the SD1, although 
structural information of their N-termini have 
hitherto been unavailable to compare their binding 
modes with that of CV-2 (22). 
    Two other known BMP-2-binding proteins – 
Collagen IIA (Col2a) and CCN3 – contain largely 
uncharacterised vWC domains (24–26). Col2a is an 
alternatively spliced form of procollagen II, 
expressed in mesenchymal and epithelial cells prior 
to differentiation (26, 27). The alternatively spliced 
exon encodes for a vWC domain, inserted in its 
non-helical N-terminal propeptide (28). This vWC 
domain is known to bind BMP-2 and confers anti-
BMP-2 activity to Col2a in bioassays (19, 24). The 
solution NMR structure of Col2a vWC has shown 
similarities to the fibronectin type 1 domain and 
CV-2 vWC1 (17, 18, 29). The N-terminal part of 
Col2a vWC is clearly different from corresponding 
part of the CV-2 vWC1, suggesting that Col2a 
vWC binds BMP-2 through an alternative, as yet 
uncharacterised mechanism (18). 
    CCN3 (also known as Nephroblastoma 
overexpressed, Nov), is a member of the CCN 
family of matricellular proteins (30). CCN3 has 
been recognised as a pro-angiogenic factor, a 
proliferation antagonist, an inhibitor of the bone 
and cartilage development, a negative regulator in 
fibrosis, as well as being involved in various types 
of cancer (31–40). CCN proteins are characterised 
by their conserved primary structure, comprised of 
four clearly distinguishable disulfide-rich domains 
(41). The vWC domain is the second domain in the 
N-terminal half for CCN proteins, following the 
insulin-like growth factor binding (IB) domain. 
These two domains are separated by a hinge region 
from the C-terminal half that contains  
thrombospondin module 1 (TSP-1) and C-terminal 
cysteine-knot (CTCK) domains (41). While it has 
been demonstrated that CCN3 binds to  BMP-2 (25), 
and that it promotes the MAP kinase signalling, 
possibly through BMP (42), the exact site of 
interaction in CCN3 is yet to be identified. 
    In order to understand the molecular mechanism 
of BMP-2 binding by Col2a and CCN3, we have 
determined crystal structures of vWC domains from 
both of these proteins and analysed their 
interactions with BMP-2. We observe both 
common and unique features in the crystal 
structures of these two vWC domains when 
compared with the existing structure of CV-2 
vWC1. Our biochemical analyses demonstrate that 
Col2a weakly binds to BMP-2 through a novel 
hydrophobic interaction on the opposite side of its 
SD1 as compared with CV-2 vWC1. However, 
despite its overall structural similarities to Col2a 
vWC, CCN3 vWC does not bind BMP-2.  
 
RESULTS 
    Crystal structures of Col2a vWC and CCN3 
vWC–In order to begin to make comparisons among 
vWC domains, we determined the structures of the 
vWC domains from both Col2a and CCN3 by X-
ray crystallography.  
The crystal structure of Col2a vWC was 
determined through sulphur SAD phasing at a 
resolution of 1.74 Å (Table 1). Like with other 
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vWC domains, the domain has an elongated shape 
with N- and C-termini at the opposite ends. As 
expected, the conserved cysteines are all involved 
in intramolecular disulfide bonds, with the same 
connectivity as seen before: C1-C4, C2-C8, C3-C5, 
C6-C9, C7-C10 (subscripted numbers refer to the 
sequential position of the cysteines in the vWC 
sequence, Fig. 1). The structure can be subdivided 
into three parts: an N-terminal β-hairpin region, a 
subdomain 1 (SD1), and a subdomain 2 (SD2; Fig. 
1A). The N-terminal region comprises a two-
stranded antiparallel β-sheet that resembles the fold 
of a β-hairpin, while SD1 consists of a three-
stranded antiparallel β-sheet with a disulfide (C3-
C5) between the last two strands. The angle between 
the N-terminal β-hairpin and SD1 is stabilised by a 
π-stacking interaction formed by two aromatic 
residues, Y41 and W47, as well as a disulfide bond 
(C1-C4) between the first strand of the β-hairpin and 
the second strand of SD1. SD2 is devoid of regular 
secondary structure, though it is tethered by one 
disulfide bond within itself (C7-C10) and by two 
disulfides to SD1 (C2-C8 and C6-C9). The two 
molecules in the asymmetric unit align well for 
most of the structure, with an overall RMSD of 
0.464 Å for 49 out of 67 residues; the main 
differences are found in the first part of SD2 (aa. 
71-77, RMSD of 1.05 Å) and in the flexible loop at 
the C-termini (aa. 89-96, RMSD of 2.49 Å) (Fig. 
S1A). 
The structure of the Col2a vWC domain has 
previously been solved by NMR (17), and an 
alignment, using only the β-hairpin and SD1,  of our 
crystal structure to the NMR ensemble is shown in 
Figure 1B. The β-hairpin and SD1 agree very well 
between the different NMR models and the crystal 
structure, with RMSD of 0.9-1.3 Å. However, we 
see much poorer overall alignment (RMSD ~3.5 Å) 
when comparing the entire structures or SD2 (Fig. 
S2). The disorder in SD2 observed in the NMR 
ensemble—particularly in the C-terminal tail after 
the last cysteine—suggests that our crystal structure 
captured one of many conformations possible for 
SD2 and that there is flexibility in both SD2 and in 
its relative orientation to SD1. Additionally, we 
observe a more extended third β-strand in SD1, a 
consequence of an extendedβ-sheet that is formed 
between the two molecules in the asymmetric unit 
of the crystal (Fig. S1B).  
    Meanwhile, the structure of CCN3 vWC was 
solved using selenomethionine labelled vWC, with 
mutations V105M/R128M to introduce 
methionines that are otherwise lacking in the 
domain. This experimentally derived mutant 
structure was then used to solve the structure of the   
wild type vWC domain and that was refined to 2.1 
Å resolution (Table 1). Similar to Col2a vWC, the 
CCN3 vWC comprises an N-terminal β-hairpin, an 
SD1 of three β-strands, and an SD2 of three β-
strands (Fig. 1C),  stabilised by five conserved 
disulfide bonds with the same connectivity. The 
angle between the β-hairpin and SD1 is also 
stabilised by a π-π interaction between two 
aromatic side chains,  Y111 and F117, and a 
disulfide bond (C1-C4). While SD2 of Col2a vWC 
is devoid of regular secondary structure, SD2 of 
CCN3 vWC consists of a three-stranded antiparallel 
β-sheet. All four molecules in the asymmetric unit 
for CCN3 vWC are nearly identical, with RMSD of 
0.121-0.338 Å (Fig. S3A). The structure of the 
V105M/R128M mutant domain aligns well with the 
wild type vWC domain, while its packing in the 
crystal is very different, suggesting that the 
orientation between the SD1/SD2 subdomains in 
CCN3 is relatively stable (data not shown).   
    Conservation analysis of Col2a vWC and CCN3 
vWC–As evolutionary conservation can reflect 
structural and/or functional importance of 
individual residues in a protein, we performed such 
analysis for the newly determined Col2a vWC and 
CCN3 vWC structures. Given the generally low 
conservation between different vWC domains, and 
possibly different molecular functions this domain 
has in different proteins, analysis of sequences from 
a single species was not deemed to be fruitful. 
Instead, we used a large number of orthologue 
sequences across different species to make sure we 
analyse conservation between functionally 
identical domains. We extracted the sequences 
from the Ensembl genome browser to ensure widest 
possible coverage of eukaryotes and removed only 
the sequences with significant stretches of poorly 
defined segments.  
    As expected, all ten cysteines are fully conserved 
across species in Col2a vWC. The two aromatic 
residues forming a π-π interaction in SD1, Y41 and 
W47 in human Col2a vWC, are also conserved for 
apparent structural importance. The tryptophan 
residue exists in all species, while the phenylalanine 
residue is found in all but one species (replaced by 
a histidine in tetraodon collagen) (Fig. S7). Besides 
this structural conservation at the core of the 
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structure, clusters of functional conservation were 
also observed in various surface positions. These 
include a hydrophobic patch in the SD1, with two 
valine residues (V46 and V56 in human Col2a) and 
a leucine residue (L63), and an isoleucine residue 
(I54), with three substitutions to valines. In SD2, 
there is another moderately conserved hydrophobic 
surface consisting of an isoleucine (I80), a 
phenylalanine (F82), and another isoleucine/valine 
residue (I88;  Fig. 5A and S7). 
    For CCN3 vWC, the cysteines are also highly 
conserved across species, with only one exception. 
In the hedgehog CCN3, three cysteines (C1, C3, and 
C6) out of ten appear to have mutated. This would 
have significant consequences for the stability of 
the domain as these changes break three of the five 
disulfides in the domain, and would disrupt the 
structure completely. Like in Col2a, both aromatic 
residues involved in the stabilisation of the N-
terminal β-hairpin and SD1 are highly conserved in 
CCN3 vWC. The tyrosine is invariable in all but 5 
out of 69 sequences, whereas the phenylalanine is 
even more conserved with substitutions to tyrosine 
found in just two species. However, unlike Col2a 
vWC, conservation of solvent exposed residues on 
the CCN3 vWC domain is less evident. The only 
cluster with relatively conserved residues is in the 
SD2. This site is comprised of P145, K153, and 
W165 in CCN3 vWC (Fig. S8), but in the absence 
of detectable binding to BMP-2 we have not studied 
the possible functional role of these residues.  
Structural comparisons among Col2a vWC, 
CCN3 vWC, and CV-2 vWC1–Besides our new 
structures and the Col2a NMR structure, the only 
other vWC structure available is that of CV-2 
vWC1 bound to BMP-2 (16). Figure 2A-C show 
pair-wise comparisons of these three structures (A, 
Col2a/CCN3; B, Col2a/CV-2; C, CCN3/CV-2). 
Generally, these three structures share common 
subdomain architectures and disulfide bond 
connections. Disulfide C1-C4  is between the N-
terminal clip (CV-2) or the first strand of N-
terminal β-hairpin (Col2a and CCN3), and the 
second strand of SD1. C3-C5 connects the second 
and third strand in SD1. The disulfide bond of C2-
C8 links SD1 with SD2, while C6-C9 and C7-C10 
form inter-strand disulfide bonds at the top and 
bottom of the SD2, respectively. While the 
connectivities of the five disulfide bonds are 
identical in all three vWC structures, detailed 
comparisons reveal subtle differences in their 
positions. In CCN3 vWC, only the C1-C4 and C3-C5 
in the N-terminal half are in the same positions as 
in Col2a and CV-2 vWCs. The lack of a proline 
residue before the C2 in CCN3 (P51 in Col2a and 
P28 in CV-2) has caused the C2-C8, and 
subsequently C9-C6, to shift their positions by one 
residue (Fig. 2D and S4). This proline residue is 
only conserved in about a quarter of all human vWC 
domains, suggesting these proteins will have 
similar spatial organisation of disulfide bonds in 
CCN3 vWC (Fig. S5). 
    While the subdomain boundaries and disulfide 
connectivities are conserved among the three 
currently available vWC structures, they display 
significant differences as well. The angles formed 
between SD1 and SD2 display great variability 
among the three structures, varying by up to 50˚. 
This is not particularly surprising, as the NMR 
ensemble of the structures of Col2a vWC and CV-
2 vWC1 domains in solution suggests significant 
flexibility in the linker between the subdomains. 
Additionally, the structural changes caused by the 
proline before the second cysteine (C2) and the shift 
of the two disulfide positions in Col2a and CV-2 
vWCs are likely to play a role in the relative 
orientation between SD1 and SD2. Previous 
investigations of CV-2 and CHL2 vWC domains 
have demonstrated that SD1 subdomains are 
responsible for BMP-2 binding, and SD2 
subdomains appear to play no direct role in this (18, 
22). 
    Superimposition of the structures shows that the 
N-terminal halves of Col2a vWC and CCN3 vWC 
domains are more similar to each other than they 
are to the corresponding part of CV-2 vWC1. Two 
major structural differences suggest that the Col2a 
and CCN3 vWC domains cannot bind BMP-2 in the 
same manner as CV-2 vWC1. Firstly, the N-
terminal regions of Col2a and CCN3 vWCs have 
more regular secondary structures compared with 
that in CV-2 vWC1 (Fig. 2A-C). The double-
stranded antiparallel β-sheet found in both Col2a 
vWC and in CCN3 vWC resembles a hairpin, 
instead of the clip-like fold in CV-2 vWC1. The 
angle between the N-terminal β-hairpin and SD1 is 
stabilised via a disulfide bond C1-C4, as well as the 
aromatic interaction between Y41 and W47 in 
Col2a, and Y111 and F117 in CCN3. While the 
equivalent disulfide bond is also observed in CV-2 
vWC1, the aromatic residues are absent and the N-
terminal part of the domain forms a more loosely 
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packed structure. As shown by Zhang et al. (18) the 
N-terminal clip of CV-2 vWC1 is very important 
for the high affinity binding to BMP-2 on the type I 
receptor binding site via hydrogen bonds. Even 
though the hydrogen bond formation is through the 
main chain atoms in CV-2 vWC1 and thus does not 
require sequence conservation, the folded β-hairpin 
structure in Col2a and CCN3 vWC domains would 
not allow their N-terminal regions to bind BMP-2 
in the same manner as CV-2 vWC1. Secondly, the 
first of the three antiparallel strands in SD1 is part 
of a regular β-sheet in Col2a vWC and CCV3 vWC, 
whereas in CV-2 vWC1 it forms an extended loop 
structure that is the other major element of the 
interface with the hydrophobic type II receptor site 
of BMP-2. Superimposition of the Col2a vWC SD1 
and CCN3 vWC SD1 with CV-2 vWC1 SD1 bound 
to BMP-2, demonstrates how the absence of the N-
terminal clip and the extended loop in the first 
strand of SD1 prevents the same interaction with 
BMP-2 (Fig. 2E). Taken together, it is unlikely that 
Col2a vWC and CCN3 vWC can bind to BMP-2 in 
the same manner as CV-2 vWC1.  
Characterisations of vWC:BMP-2 interactions–
To support our structural analyses that suggest new 
modes of vWC:BMP-2 interactions, we set about 
characterising the binding of Col2a and CCN3 
vWC domains to BMP-2 using surface plasmon 
resonance (SPR). Purified recombinant mature 
domain of BMP-2 was covalently immobilised on 
the surface of the sensor chip, and purified Col2a 
and CCN3 vWC domains were flowed over the 
sensor chip. As has been shown previously (19, 24), 
Col2a vWC was found to bind to BMP-2, albeit at 
low affinity. The binding rate constants koff (7x10-3 
s-1) and kon (7x102 M-1s-1) were determined by 
fitting kinetic data to a 1:1 binding model, resulting 
in a KD of 10 μM (KD = koff/kon) (Fig. 3A). This 
calculated binding affinity was validated by 
equilibrium SPR experiments, resulting in a KD 
of 42 μM (Fig. 3B).  
However, despite having a similar SD1 structure 
to Col2a vWC, CCN3 vWC did not show any 
detectable binding to BMP-2 at concentration range 
up to 40 μM when analysed by SPR in identical 
conditions used for Col2a vWC (Fig. 3C). Given 
that we use highly purified and homogenous protein, 
we are very confident that interaction between 
BMP-2 and CCN3 (and most likely other CCN 
proteins) is not mediated by the vWC domain, or, at 
most, its contribution to the binding is very small.  
    Based on these structural and biophysical data, it 
is clear that the residues responsible for BMP-2 
binding in the Col2a vWC are unlikely to be the 
same as in CV-2 vWC1. Given that structurally 
more similar CCN3 vWC is not binding to BMP-2, 
the BMP-2 binding residues in Col2a would not be 
conserved in CCN3 either. To define the binding 
epitope of Col2a vWC to BMP-2, we identified two 
conserved clusters of surface-exposed hydrophobic 
residues: I. V46, I54, V56, L63, and I67 in SD1, and 
II. I80, F82, and I88 in SD2 (Fig. 4A and 5A). Site 
I in SD1 is in the opposite side to the CV-2 vWC1 
epitope, whereas the site in the SD2 is directly 
below the CV-2 vWC1 epitope. We mutated these 
residues in pairs (based on closeness in the 3D 
structure) to alanines, generating four mutants of 
Col2a vWC (Fig. 4A). All the mutants were 
expressed and purified as the wild type domain, 
appearing to produce well-folded proteins. 
    The effect of these mutations on the interaction 
with BMP-2 was monitored by SPR. These SPR 
experiments revealed that all three mutants 
containing mutations in site I, V46A+I54A, 
V56A+L63A, and I67A+I80A, showed no 
interaction with BMP-2, whereas the F82A+I88A 
mutant, with both residues in site II, retained its 
ability to bind BMP-2 (Fig. 4B-G). Since the 
interaction between the Col2a vWC and BMP-2 is 
weak (KD 10-42 μM), it is not surprising that 
mutation of one or two residues involved in the 
binding can be enough to completely disrupt the 
interaction. Taken together, it can be inferred that 
the binding epitope of Col2a vWC to BMP-2 
resides in site I, on the opposite side of SD1 to the 
CV-2 vWC1 epitope, with residues V46 and/or I54, 
V56 and/or L63, and I67 contributing to the 
hydrophobic interactions with BMP-2. 
 
DISCUSSION 
    We have determined the structures of the vWC 
domains of collagen IIA and CCN3 using X-ray 
crystallography. Through structural comparison 
with CV-2 vWC1, we predict that Col2a vWC and 
CCN3 vWC are not able to bind to BMP-2 in the 
same manner as CV-2 vWC1. Using SPR, we 
analysed the binding of the two vWC domains of 
collagen IIA and CCN3 to BMP-2. Kinetic rate 
constants of the Col2a vWC:BMP-2 interaction 
were measured, and the binding affinity was 
determined using both kinetic and equilibrium SPR 
data. CCN3 vWC, on the other hand, showed no 
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binding to BMP-2 at the same concentration range 
used as Col2a vWC. Leveraging our structural 
analysis, we identified the binding epitope of Col2a 
vWC to BMP-2 as a hydrophobic patch on the 
opposite side of SD1 as the previously 
characterised BMP-2 binding site in CV-2 vWC1. 
    Both Col2a and CCN3 vWC domains show a 
typical tripartite structure of an N-terminal region, 
and two subdomains SD1 and SD2. The non-
globular, extended confirmation of the vWC 
domains potentially allows a great deal of 
flexibility for the relative orientation of SD2 to SD1, 
as has been observed in solution NMR structures of 
Col2a vWC and CV-2 vWC1 (17, 23). Given this 
flexibility, the hydrogen bond network between β-
sheets in adjacent molecules in the asymmetric 
units of both Col2a and CCN3 vWCs must be key 
contributions to the well-diffracting crystals (Fig. 
S1B and S3B). As commonly observed in most 
cysteine-rich extracellular proteins, the formation 
of the disulfide bonds are largely responsible for the 
stability of this small domain, reflected in the 
complete conservation of these residues. One of the 
unique features that we observe in Col2a vWC and 
CCN3 vWC, but not in CV-2 vWC1, is the π-π 
interaction that locks the orientation of the N-
terminal β-hairpin. The two aromatic residues that 
form this π-π interaction, one in the N-terminal 
region and the other in the SD1, are conserved in 
more than half (162 out of 259) of the vWC 
domains found in human proteins (Fig. S6), 
including vWC domains known to bind BMP-2 
(Fig. 5B). These vWC domains would potentially 
share the N-terminal structure of the β-hairpin with 
Col2a vWC and CCN3 vWC, rather than the 
extended clip-like fold found in CV-2 vWC1. 
    The two major binding epitopes for BMP-2 in 
CV-2 vWC1, the N-terminal clip and the extended 
first strand in SD1, are both absent in our Col2a 
vWC and CCN3 vWC structures. It was suggested 
by Zhang et al. (18) that the Col2a vWC could 
undergo major conformational rearrangements to 
make the same epitope accessible for binding to 
BMP-2. However, a solution NMR structure of the 
CV-2 vWC1 in its unbound state showed that the 
conformations of both epitopes were pre-defined, 
with the angle of the N-terminal clip relative to SD1 
being fixed and the extended first strand in SD1 
being very rigid (23). Instead, our mutational study 
on Col2a vWC has uncovered a novel BMP-2 
binding epitope on the opposite side of SD1 as 
compared with that in the CV-2 vWC1. Sequence 
conservation analysis has also shown that this 
epitope is highly conserved across different species, 
with a score of 9 (9 to 1 from conserved to variable) 
for V46, V56, and L63, 8 for I54, and 7 for I67 (Fig. 
5A and S7). Since the structure of the CCN3 vWC 
revealed no conservation of either of the two CV-2 
vWC1 epitopes nor the residues involved in binding 
in Col2a vWC, it is not surprising that we did not 
observe any binding of CCN3 vWC to BMP-2. 
However, the association between the CCN family 
and the BMPs is clearly evident in the literature (25, 
43–48), therefore this interaction must be mediated 
through one or more of the three other domains (IB, 
TSP1, or CTCK) in the CCN proteins. 
    This new mechanism of vWC:BMP interaction 
provides insights into the possible binding modes 
of other BMP-binding vWC domains (Table 2 and 
Fig. 5B). For Chordin and CHL2, their vWC1 and 
vWC3 were both shown to bind BMP-2 in the SD1 
(22). Residues involved in the binding in CHL2 
vWC1 and vWC3 were also identified by 
mutational analysis by Fujisawa et al (22). 
Sequence alignment with Col2a vWC and CV-2 
vWC1 suggests that these residues lie in the first 
strand of SD1 (Fig. 5B), and given that CHL2 and 
Chordin possess 7-10 more residues in this region, 
it is possible that they form an even more extended 
loop towards the BMP-2 and share the same epitope 
with CV-2 vWC1. However, the two aromatic 
residues that form the π-π interaction between the 
N-terminal region and SD1 may make it 
conformationally more preferable to access BMP-2 
from the opposite side as we have shown for the 
Col2a vWC. It is also possible that these vWC 
domains bind BMP-2 through yet another epitope, 
and further studies are necessary to parse this 
question. 
    Besides CV-2, previous studies have revealed 
inhibition mechanisms of other known antagonists 
of BMP signalling, typically through blocking the 
type I and type II receptor binding sites. Similar to 
CV-2, both Noggin and Gremlin-2 utilise their 
flexible and extended N-terminal regions to reach 
into the type I receptor binding site of BMP, 
together with additional interfaces that overlap with 
the type II receptor site (11, 14). Gremlin-1 also 
shares the binding sites of both type I and II 
receptors, although not involving its N-termini (12). 
Despite similar inhibition mechanisms, the 
stoichiometries of these antagonists with their 
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ligand BMPs are quite diverse. One dimeric Noggin 
binds to one dimeric BMP with a 1:1 stoichiometry, 
whereas two molecules of CV-2 vWC1 bind to each 
protomer of a dimeric BMP with a 2:1 
stoichiometry. For Gremlin-1 and -2, distinguished 
features of elongated fibrils of oligomeric 
complexes have been suggested, where each 
protomer of a dimeric Gremlin binds to one 
protomer of BMP, forming an alternating, open-
ended oligomer  (12, 14). To elucidate the binding 
mechanism by Col2a, future studies should include 
mutagenesis of receptor binding sites on BMP-2, 
complex crystallisation, and small-angle X-ray 
scattering analysis. 
    The affinity of Col2a vWC for BMP-2 we 
obtained is much lower when comparing with the 
vWC domains in CV-2, Chordin and CHL2 (Table 
2). However, the affinity of full-length Chordin and 
CHL2, which allows multiple vWC domains to 
simultaneously bind BMP-2, is 7.5-2500 fold 
higher than their individual vWC domains (Table 2) 
(18, 21, 22, 49). In vivo, collagen molecules self-
associate into trimeric coils and to further 
oligomeric fibrils, with the vWC domain containing 
N-terminal propeptide accessible on the surface of 
the collagen fibrils (24).  Multimeric collagen could 
allow two vWC domains to interact simultaneously 
with a dimeric BMP-2, forming oligomeric fibrils 
like the Gremlins (12, 14), and thereby increase the 
apparent affinity between the two proteins due to 
avidity effects. In fact, Col2a vWC expressed as a 
GST fusion protein has been shown to bind BMP-2 
with nanomolar affinity (24). Furthermore, 
previous studies with Xenopus laevis oocytes 
demonstrated anti-BMP-2 activity with full-length 
collagen IIA but not with isolated Col2a vWC 
domain (19), suggesting that avidity effects play a 
significant role in the biological efficacy of Col2a 
vWC. BMPs are also thought to bind to fibrillar 
collagen directly and such interactions could exist 
alongside vWC binding, and further stabilise such 
complex. Furthermore, like all TGF-β family 
growth factors, BMPs are synthesised as larger 
precursors and the pro-peptides can interact with 
components of the extracellular matrix (50). Col2a 
vWC interaction is therefore one of the many ways 
BMPs interact with ECM. 
    As collagen is a major structural component of 
the extracellular matrix, its binding of BMP-2 could 
affect the localisation and generation of 
morphogenetic gradients during development. 
Procollagen IIA is expressed in epithelial and 
mesenchymal cells prior to differentiation, 
suggesting it may play an important role in tissue 
differentiation and body patterning (26–28). In our 
biological activity assays, we did not observe 
inhibition or stimulation of the BMP-2 signalling 
by monomeric Col2a vWC (data not shown). This 
could be due to the low affinity binding by a single 
vWC domain rather than the trimeric full-length 
collagen. Alternatively, the binding to BMP-2 by 
collagen could be neutral with regards to BMP-2 
bioactivity, with collagen instead serving as a 
scaffold for localisation and storage of BMP-2, 
assisting in its gradient formation and presenting it 
to other extracellular regulators. While we have not 
been able to characterise the BMP-2:Col2a vWC 
complex structurally, our data suggest distinct 
mode of interaction that has been observed with 
CV-2 and noggin.  Localisation of the BMP-2-
binding epitope on the relatively flat surface of the 
Col2a vWC domain suggests that this interaction 
cannot involve both the type I and II receptor 
binding sites, which are located on the opposite 
sides of the growth factor.     
 
EXPERIMENTAL PROCEDURES 
Cloning, Expression, and Purification–Human 
collagen IIA vWC domain (residues 31-98, Uniprot 
P02458) and rat CCN3 vWC domain (residues 100-
195, Uniprot Q9QZQ5) were expressed in 
BL21(DE3) E. coli using the pHAT3 and pBAT4 
vectors (51), respectively. DNA for the Col2a vWC 
construct was codon optimised for E. coli and 
synthesised by PCR using overlapping 
oligonucleotides (all oligonucleotide sequences are 
listed in the Supplementary material). CCN3 was 
amplified from cDNA (kind gift from Dr Paul 
Kemp).  vWC mutants were generated by a two-
step PCR protocol using overlapping 
oligonucleotide across the mutated regions and 
cloned into expression vectors as the wild type 
proteins. All constructs were confirmed by dideoxy 
sequencing. For protein expression, E. coli 
BL21(DE3) competent cells of were transformed 
with the expression plasmid and grown on L-agar 
plates in the presence of 100 g/ml of ampicillin 
overnight. The following day, cells from the plate 
were cultured in 2-YT medium with 100 g/ml 
ampicillin at 37 °C under agitation. Cells were 
induced with 400 μM isopropyl-β-D-
BMP-2 binding of vWC domains of Collagen IIA and CCN3 
 8 
thiogalactoside at an OD600nm of 0.8 and left to 
express the proteins for 4 h. Both proteins were 
expressed solubly, despite the presence of 10 
cysteines that form disulfide bridges in the folded 
proteins.  
His-tagged Col2a vWC was purified by Ni-NTA 
affinity chromatography, followed by cleavage of 
the His-tag by thrombin protease, and final 
purification by reversed phase chromatography 
(ACE® 5 C8-300). CCN3 vWC was purified by 
anion exchange (HiTrap™ Q HP, GE Healthcare) 
and size exclusion chromatographies (HiLoad™ 
16/60 Superdex™ 75, GE Healthcare) followed by 
reversed phase chromatography (ACE® 5 C8-300). 
Both proteins were lyophilised and resuspended in 
water after reverse phase chromatography. Purified 
proteins were analysed by MALDI mass 
spectrometry and were observed to have the mass 
for proteins in which all cysteine residues have been 
oxidised to cystines. In order to obtain experimental 
phases for CCN3 vWC crystal structure 
determination, the V105M/R128M mutant protein 
was labelled with selenomethionine using the 
metabolic suppression method and purified like the 
wild type domain.  
Production of BMP-2 has been described 
previously (12).  
    Crystallisation and structure determination–
Crystals of the SeMet-labelled CCN3 vWC mutant 
grew in 3.4 M NaCl, 100 mM MES pH 6.8, in 1 l 
+ 1l drops.  Crystals were cryoprotected with 10% 
glycerol and cryocooled in liquid nitrogen. Data 
from these crystals were collected at ESRF 
beamline BM14 at Selenium peak at a wavelength 
of 0.97963 Å. Data were processed using XDS and 
the experimental phases were derived from the 
SAD data using autoSHARP (52). The initial model 
was  built automatically using ARP/wARP (53). 
Crystals of unlabelled CCN3 vWC domain grew in 
0.8 M K/Na tartrate, 0.4 M NaCl, 0.1 M imidazole 
pH 8.0.  The crystals were cryo-protected in 30 % 
glycerol and cryo-cooled in liquid nitrogen. X-ray 
diffraction data were collected at Diamond Light 
Source, beamline I04-1, using a Pilatus 2M detector 
(Dectris, Switzerland), at wavelength 0.9173 Å. X-
ray diffraction data of CCN3 vWC were indexed, 
integrated, and scaled using XDS (54). Two 
datasets obtained from separate crystals were 
merged using XSCALE (54). Molecular 
replacement was performed by AMoRe (55), using 
the experimentally phased CCN3 vWC 
V105M/R128M mutant structure as the search 
model. Refinement was performed using Refmac 
5.5 (56) and Phenix 1.8.4 (57). Coot  (58) was used 
for iterative model building and initial validation.  
    Col2a vWC domain was crystallised by mixing 1 
uL protein at a concentration of 10 mg/mL and 1 uL 
reservoir solution (0.1 M HEPES, pH 7.5, 40% 
PEG 200) in a sitting drop vapour diffusion setup. 
Experimental phases were obtained from sulphur 
single wavelength anomalous dispersion (SAD). 
Anomalous data were collected at a wavelength of 
1.9 Å at beamline I04 of Diamond Light Source and 
processed via autoPROC (59). Phases were 
obtained using ShelxC, ShelxD, and ShelxE (60) 
through the HKL2MAP (61) interface. An initial 
model was obtained through automated model 
building using Buccaneer (62). Further iterative 
model building was performed using autoBUSTER 
(63) and Coot (58). This preliminary model was 
then used in molecular replacement (PHASER 
(64)) to extend the resolution to data collected at a 
wavelength of 0.9686 Å at beamline I24 at 
Diamond Light Source and refined as above. 
    Statistics of X-ray data collection and structure 
refinement are shown in Table 1. Both Col2a and 
CCN3 vWC structures have been deposited in the 
Protein Data Bank with accession codes 5NIR and 
5NB8, respectively.  
    Conservation analysis–The degree of 
evolutionary conservation of the amino acids in the 
Col2a vWC and CCN3 vWC domains was analysed 
using the ConSurf server (http://consurf.tau.ac.il/) 
(65), in order to reveal the regions that are 
important for the function and/or structure of the 
protein. Sequences of Col2a vWC and CCN3 vWC 
across species were extracted from the Ensembl 
database (release 86, http://www.ensembl.org/ 
index.html), aligned and scored for position-
specific conservation by the ConSurf Server, and 
mapped onto the surfaces of the corresponding 
structures  (65). 
    Surface plasmon resonance (SPR)–SPR binding 
assays were performed on a BIAcore T100 
instrument (GE Healthcare). HBS-EP+ buffer (20 
mM HEPES, 150 mM NaCl, 3 mM EDTA, 0.05% 
(v/v) Surfactant P20, pH 7.4) with the addition of 1 
mg/ml CM-Dextran salt was used as the running 
buffer at a flow rate of 30 μl/min. BMP-2 (residues 
283-396) was directly immobilised on a CM5 
sensor chip (GE Healthcare) via amine coupling. 
Wild-type and mutants of Col2a vWC, as well as 
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the CCN3 vWC, were used as analytes. The surface 
was regenerated with 4 M guanidinium chloride. 
The sensograms were corrected for unspecific 
binding by subtracting the signal from the reference 
channel. Data were analysed with BIAcore T100 
Evaluation Software 2.0.3 (GE Healthcare) and 
proFit (QuantumSoft) using kinetic and equilibrium 
equations for a 1:1 interaction.  
 
 
ACKNOWLEDGEMENTS 
We thank Ms Katharina Ravn for the production of BMP-2 and Dr May Marsh for her help with 
crystallisation. We are grateful for access to and support at the X-ray crystallographic and Biophysics 
facilities at the Department of Biochemistry. We thank the Diamond Light Source and the beamline staff 
for access to beamline i02, i04-1 and i24 (proposals mx6886 and mx7141, respectively), and ESRF and 
their beamline staff for access to beamline BM14. This work was supported by Cambridge Overseas Trust 
and China Scholarship Council through a postgraduate scholarship to E-R. X. The atomic coordinates and 
structure factors (5NB8 for CCN3 vWC domain and 5NIR for Col2a vWC domain) have been deposited in 
the Protein Data Bank. 
 
CONFLICT OF INTEREST 
The authors declare that they have no conflicts of interest with the contents of this article. 
 
AUTHOR CONTRIBUTIONS 
MH conceived and coordinated the study and E-RX, EEB, and MH designed the experiments. EEB 
performed the experiments with Col2a vWC domain, E-RX performed the experiments with CCN3 vWC 
domain and Col2a vWC mutants. GF determined the structure of Col2a vWC domain, MH determined the 
original CCN3 vWC domain. All authors analysed the results, wrote, revised, and approved the final version 
of the manuscript. E-RX and EEB contributed equally and are equal first authors.  
 
FOOTNOTES 
The abbreviations used are: BMP, bone morphogenetic protein; vWC, von Willebrand factor C domain; 
Col2a, collagen type II; CV-2, Crossveinless-2; CHL2, Chordin-like 2; Nov, Nephroblastoma 
overexpressed; SPR, surface plasmon resonance 
 
REFERENCES 
1.  Hogan, B. L. M. (1996) Bone morphogenetic proteins in development. Curr. Opin. Genet. Dev. 6, 
432–438 
2.  Reddi, A. (2003) Cartilage morphogenetic proteins: role in joint development, homoeostasis, and 
regeneration. Ann. Rheum. Dis. 62, ii73-ii78 
3.  Simic, P., and Vukicevic, S. (2005) Bone morphogenetic proteins in development and homeostasis 
of kidney. Cytokine Growth Factor Rev. 16, 299–308 
4.  Moura, J., Da Silva, L., Cruz, M. T., and Carvalho, E. (2013) Molecular and cellular mechanisms 
of bone morphogenetic proteins and activins in the skin: Potential benefits for wound healing. 
Arch. Dermatol. Res. 305, 557–569 
5.  Tobin, J. F., and Celeste, A. J. (2006) Bone morphogenetic proteins and growth differentiation 
factors as drug targets in cardiovascular and metabolic disease. Drug Discov. Today. 11, 405–411 
6.  Manson, S. R., Song, J. B., Guo, Q., Liapis, H., and Austin, P. F. (2015) Cell type specific changes 
in BMP-7 expression contribute to the progression of kidney disease in patients with obstructive 
uropathy. J. Urol. 193, 1860–1869 
7.  Cai, J., Pardali, E., Sánchez-Duffhues, G., and Ten Dijke, P. (2012) BMP signaling in vascular 
BMP-2 binding of vWC domains of Collagen IIA and CCN3 
 10 
diseases. FEBS Lett. 586, 1993–2002 
8.  Bandyopadhyay, A., Yadav, P. S., and Prashar, P. (2013) BMP signaling in development and 
diseases: A pharmacological perspective. Biochem. Pharmacol. 85, 857–864 
9.  Miyazono, K., Kamiya, Y., and Morikawa, M. (2010) Bone morphogenetic protein receptors and 
signal transduction. J. Biochem. 147, 35–51 
10.  Balemans, W., and Van Hul, W. (2002) Extracellular regulation of BMP signaling in vertebrates: 
A cocktail of modulators. Dev. Biol. 250, 231–250 
11.  Groppe, J., Greenwald, J., Wiater, E., Rodriguez-Leon, J., Economides, A. N., Kwiatkowski, W., 
Affolter, M., Vale, W. W., Belmonte, J. C. I., and Choe, S. (2002) Structural basis of BMP 
signalling inhibition by the cystine knot protein Noggin. Nature. 420, 636–642 
12.  Kišonaitė, M., Wang, X., and Hyvönen, M. (2016) Structure of Gremlin-1 and analysis of its 
interaction with BMP-2. Biochem. J. 473, 1593–604 
13.  Salazar, V. S., Gamer, L. W., and Rosen, V. (2016) BMP signalling in skeletal development, 
disease and repair. Nat. Rev. Endocrinol. 12, 203–221 
14.  Nolan, K., Kattamuri, C., Rankin, S. A., Read, R. J., Zorn, A. M., and Thompson, T. B. (2016) 
Structure of Gremlin-2 in Complex with GDF5 Gives Insight into DAN-Family-Mediated BMP 
Antagonism. Cell Rep. 16, 2077–2086 
15.  Nolan, K., Kattamuri, C., Luedeke, D. M., Deng, X., Jagpal, A., Zhang, F., Linhardt, R. J., Kenny, 
A. P., Zorn, A. M., and Thompson, T. B. (2013) Structure of protein related to DAN and Cerberus: 
Insights into the mechanism of bone morphogenetic protein antagonism. Structure. 21, 1417–1429 
16.  Mancuso, D. J., Tuley, E. A., Westfield, L. a, Worrall, N. K., Shelton-Inloes, B. B., Sorace, J. M., 
Alevy, Y. G., and Sadler, J. E. (1989) Structure of the gene for human von Willebrand factor. J. 
Biol. Chemystry. 264, 19514–19527 
17.  O’Leary, J. M., Hamilton, J. U., Deane, C. M., Valeyev, N. V., Sandell, L. J., and Downing, A. K. 
(2004) Solution structure and dynamics of a prototypical chordin-like cysteine-rich repeat (von 
Willebrand factor type C module) from collagen IIA. J. Biol. Chem. 279, 53857–53866 
18.  Zhang, J. li, Qiu, L. yan, Kotzsch, A., Weidauer, S., Patterson, L., Hammerschmidt, M., Sebald, 
W., and Mueller, T. D. (2008) Crystal Structure Analysis Reveals How the Chordin Family 
Member Crossveinless 2 Blocks BMP-2 Receptor Binding. Dev. Cell. 14, 739–750 
19.  Larraín, J., Bachiller, D., Lu, B., Agius, E., Piccolo, and Robertis, D. (2000) BMP-binding 
modules in chordin: a model for signalling regulation in the extracellular space. Development. 127, 
821–830 
20.  Garcia Abreu, J., Coffinier, C., Larraín, J., Oelgeschläger, M., and De Robertis, E. M. (2002) 
Chordin-like CR domains and the regulation of evolutionarily conserved extracellular signaling 
systems. Gene. 287, 39–47 
21.  Zhang, J.-L., Huang, Y., Qiu, L.-Y., Nickel, J., and Sebald, W. (2007) von Willebrand factor type 
C domain-containing proteins regulate bone morphogenetic protein signaling through different 
recognition mechanisms. J. Biol. Chem. 282, 20002–20014 
22.  Fujisawa, T., Huang, Y., Sebald, W., and Zhang, J. L. (2009) The binding of von Willebrand 
factor type C domains of Chordin family proteins to BMP-2 and Tsg is mediated by their SD1 
subdomain. Biochem. Biophys. Res. Commun. 385, 215–219 
23.  Fiebig, J. E., Weidauer, S. E., Qiu, L. Y., Bauer, M., Schmieder, P., Beerbaum, M., Zhang, J. L., 
Oschkinat, H., Sebald, W., and Mueller, T. D. (2013) The clip-segment of the von Willebrand 
domain 1 of the BMP modulator protein crossveinless 2 is preformed. Molecules. 18, 11658–
BMP-2 binding of vWC domains of Collagen IIA and CCN3 
 11 
11682 
24.  Zhu, Y., Oganesian, A., Keene, D. R., and Sandell, L. J. (1999) Type IIA Procollagen Containing 
the Cysteine-rich Amino Propeptide Is Deposited in the Extracellular Matrix of Prechondrogenic. 
J. Cell Biol. 144, 1069–1080 
25.  Minamizato, T., Sakamoto, K., Liu, T., Kokubo, H., Katsube, K. ichi, Perbal, B., Nakamura, S., 
and Yamaguchi, A. (2007) CCN3/NOV inhibits BMP-2-induced osteoblast differentiation by 
interacting with BMP and Notch signaling pathways. Biochem. Biophys. Res. Commun. 354, 567–
573 
26.  Ryan, M. C., and Sandell, L. J. (1990) Differential expression of a cysteine-rich domain in the 
amino-terminal propeptide of type II (cartilage) procollagen by alternative splicing of mRNA. J. 
Biol. Chem. 265, 10334–10339 
27.  Sandell, L. J., Nalin, A. M., and Reife, R. A. (1994) Alternative splice form of type II procollagen 
mRNA (IIA) is predominant in skeletal precursors and non-cartilaginous tissues during early 
mouse development. Dev. Dyn. 199, 129–140 
28.  Oganesian, A., Zhu, Y., and Sandell, L. J. (1997) Type IIA Procollagen Amino Propeptide Is 
Localized in Human Embryonic Tissues. J. Histochem. Cytochem. 45, 1469–1480 
29.  Williams, M. J., Phan, I., Harvey, T. S., Rostagno, A., Gold, L. I., and Campbell, I. D. (1994) 
Solution structure of a pair of fibronectin type 1 modules with fibrin binding activity. J. Mol. Biol. 
235, 1302–1311 
30.  Leask, A., and Abraham, D. J. (2006) All in the CCN family: essential matricellular signaling 
modulators emerge from the bunker. J. Cell Sci. 119, 4803–4810 
31.  Lin, C. G., Leu, S. J., Chen, N., Tebeau, C. M., Lin, S. X., Yeung, C. Y., and Lau, L. F. (2003) 
CCN3 (NOV) is a novel angiogenic regulator of the CCN protein family. J. Biol. Chem. 278, 
24200–24208 
32.  Bleau, A. M., Planque, N., Lazar, N., Zambelli, D., Ori, A., Quan, T., Fisher, G., Scotlandi, K., 
and Perbal, B. (2007) Antiproliferative activity of CCN3: Involvement of the C-terminal module 
and post-translational regulation. J. Cell. Biochem. 101, 1475–1491 
33.  Rydziel, S., Stadmeyer, L., Zanotti, S., Durant, D., Smerdel-Ramoya, A., and Canalis, E. (2007) 
Nephroblastoma overexpressed (Nov) inhibits osteoblastogenesis and causes osteopenia. J. Biol. 
Chem. 282, 19762–19772 
34.  Janune, D., Kubota, S., Nishida, T., Kawaki, H., Perbal, B., Iida, S., and Takigawa, M. (2011) 
Novel effects of CCN3 that may direct the differentiation of chondrocytes. FEBS Lett. 585, 3033–
3040 
35.  Abd El Kader, T., Kubota, S., Janune, D., Nishida, T., Hattori, T., Aoyama, E., Perbal, B., Kuboki, 
T., and Takigawa, M. (2013) Anti-fibrotic effect of CCN3 accompanied by altered gene 
expression profile of the CCN family. J. Cell Commun. Signal. 7, 11–18 
36.  Ohgawara, T., Kubota, S., Kawaki, H., Kurio, N., Abd El Kader, T., Hoshijima, M., Janune, D., 
Shimo, T., Perbal, B., Sasaki, A., and Takigawa, M. (2011) Association of the metastatic 
phenotype with CCN family members among breast and oral cancer cells. J. Cell Commun. Signal. 
5, 291–299 
37.  Cui, L., Xie, R., Dang, S., Zhang, Q., Mao, S., Chen, J., Qu, J., and Zhang, J. (2014) NOV 
promoted the growth and migration of pancreatic cancer cells. Tumor Biol. 35, 3195–3201 
38.  McCallum, L., Price, S., Planque, N., Perbal, B., Pierce, A., Whetton, A. D., and Irvine, A. E. 
(2006) A novel mechanism for BCR-ABL action: Stimulated secretion of CCN3 is involved in 
growth and differentiation regulation. Blood. 108, 1716–1723 
BMP-2 binding of vWC domains of Collagen IIA and CCN3 
 12 
39.  Ouellet, V., and Siegel, P. M. (2012) CCN3 modulates bone turnover and is a novel regulator of 
skeletal metastasis. J. Cell Commun. Signal. 6, 73–85 
40.  Chang, C. C., Lin, B. R., Wu, T. S., Jeng, Y. M., and Kuo, M. L. (2014) Input of 
microenvironmental regulation on colorectal cancer: Role of the CCN family. World J. 
Gastroenterol. 20, 6826–6831 
41.  Bork, P. (1993) The modular architecture of a new family of growth regulators related to 
connective tissue growth factor. FEBS Lett. 327, 125–130 
42.  Kawaki, H., Kubota, S., Suzuki, A., Suzuki, M., Kohsaka, K., Hoshi, K., Fujii, T., Lazar, N., 
Ohgawara, T., Maeda, T., Perbal, B., Takano-Yamamoto, T., and Takigawa, M. (2011) 
Differential roles of CCN family proteins during osteoblast differentiation: Involvement of Smad 
and MAPK signaling pathways. Bone. 49, 975–989 
43.  Abreu, J. G., Ketpura, N. I., Reversade, B., and De Robertis, E. M. (2002) Connective-tissue 
growth factor (CTGF) modulates cell signalling by BMP and TGF-beta. Nat. Cell Biol. 4, 599–604 
44.  Nakamura, Y., Weidinger, G., Liang, J. O., Aquilina-Beck, A., Tamai, K., Moon, R. T., and 
Warman, M. L. (2007) The CCN family member Wisp3, mutant in progressive pseudorheumatoid 
dysplasia, modulates BMP and Wnt signaling. J. Clin. Invest. 117, 3075–3086 
45.  Nguyen, T. Q., Roestenberg, P., van Nieuwenhoven, F. A., Bovenschen, N., Li, Z., Xu, L., Oliver, 
N., Aten, J., Joles, J. A., Vial, C., Brandan, E., Lyons, K. M., and Goldschmeding, R. (2008) 
CTGF inhibits BMP-7 signaling in diabetic nephropathy. J. Am. Soc. Nephrol. 19, 2098–2107 
46.  Maeda, A., Nishida, T., Aoyama, E., Kubota, S., Lyons, K. M., Kuboki, T., and Takigawa, M. 
(2009) CCN family 2/connective tissue growth factor modulates BMP signalling as a signal 
conductor, which action regulates the proliferation and differentiation of chondrocytes. J. 
Biochem. 145, 207–216 
47.  Ono, M., Inkson, C. A., Kilts, T. M., and Young, M. F. (2011) WISP-1/CCN4 regulates 
osteogenesis by enhancing BMP-2 activity. J. Bone Miner. Res. 26, 193–208 
48.  Pal, A., Huang, W., Li, X., Toy, K. A., Nikolovska-Coleska, Z., and Kleer, C. G. (2012) CCN6 
modulates BMP signaling via the Smad-independent TAK1/p38 pathway, acting to suppress 
metastasis of breast cancer. Cancer Res. 72, 4818–4828 
49.  Troilo, H., Zuk, A. V, Tunnicliffe, R. B., Wohl, A. P., Berry, R., Collins, R. F., Jowitt, T. A., 
Sengle, G., and Baldock, C. (2014) Nanoscale structure of the BMP antagonist chordin supports 
cooperative BMP binding. Proc. Natl. Acad. Sci. U. S. A. 111, 13063–13068 
50.  Wohl, A. P., Troilo, H., Collins, R. F., Baldock, C., and Sengle, G. (2016) Extracellular regulation 
of bone morphogenetic protein activity by the microfibril component fibrillin-1. J. Biol. Chem. 
291, 12732–12746 
51.  Peränen, J., Rikkonen, M., Hyvönen, M., and Kääriäinen, L. (1996) T7 vectors with modified 
T7lac promoter for expression of proteins in Escherichia coli. Anal. Biochem. 236, 371–373 
52.  Bricogne, G., Vonrhein, C., Flensburg, C., Schiltz, M., and Paciorek, W. (2003) Generation, 
representation and flow of phase information in structure determination: Recent developments in 
and around SHARP 2.0. Acta Crystallogr. - Sect. D Biol. Crystallogr. 59, 2023–2030 
53.  Langer, G., Cohen, S. X., Lamzin, V. S., and Perrakis, A. (2008) Automated macromolecular 
model building for X-ray crystallography using ARP/wARP version 7. Nat. Protoc. 3, 1171–1179 
54.  Kabsch, W. (2010) Xds. Acta Crystallogr. Sect. D Biol. Crystallogr. 66, 125–132 
55.  Navaza, J. (1994) AMoRe: an automated package for molecular replacement. Acta Crystallogr. 
Sect. A. 50, 157–163 
BMP-2 binding of vWC domains of Collagen IIA and CCN3 
 13 
56.  Vagin, A. A., Steiner, R. A., Lebedev, A. A., Potterton, L., McNicholas, S., Long, F., and 
Murshudov, G. N. (2004) REFMAC5 dictionary: Organization of prior chemical knowledge and 
guidelines for its use. Acta Crystallogr. Sect. D Biol. Crystallogr. 60, 2184–2195 
57.  Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., 
Hung, L. W., Kapral, G. J., Grosse-Kunstleve, R. W., McCoy, A. J., Moriarty, N. W., Oeffner, R., 
Read, R. J., Richardson, D. C., Richardson, J. S., Terwilliger, T. C., and Zwart, P. H. (2010) 
PHENIX: A comprehensive Python-based system for macromolecular structure solution. Acta 
Crystallogr. Sect. D Biol. Crystallogr. 66, 213–221 
58.  Emsley, P., and Cowtan, K. (2004) Coot: Model-building tools for molecular graphics. Acta 
Crystallogr. Sect. D Biol. Crystallogr. 60, 2126–2132 
59.  Vonrhein, C., Flensburg, C., Keller, P., Sharff, A., Smart, O., Paciorek, W., Womack, T., and 
Bricogne, G. (2011) Data processing and analysis with the autoPROC toolbox. Acta Crystallogr. 
Sect. D Biol. Crystallogr. 67, 293–302 
60.  Sheldrick, G. M. (2007) A short history of SHELX. Acta Crystallogr. Sect. A Found. Crystallogr. 
64, 112–122 
61.  Pape, T., and Schneider, T. R. (2004) HKL2MAP : a graphical user interface for macromolecular 
phasing with SHELX programs. J. Appl. Crystallogr. 37, 843–844 
62.  Cowtan, K. (2006) The Buccaneer software for automated model building. 1. Tracing protein 
chains. Acta Crystallogr. Sect. D Biol. Crystallogr. 62, 1002–1011 
63.  Bricogne G., Blanc E., Brandl M., Flensburg C., Keller P., P. W., and Roversi P, Sharff A., Smart 
O.S., Vonrhein C., W. T. O. (2016) BUSTER version 2.11.5. Cambridge, United Kingdom Glob. 
Phasing Ltd. 
64.  McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., and Read, R. 
J. (2007) Phaser crystallographic software. J. Appl. Crystallogr. 40, 658–674 
65.  Ashkenazy, H., Abadi, S., Martz, E., Chay, O., Mayrose, I., Pupko, T., and Ben-Tal, N. (2016) 
ConSurf 2016: an improved methodology to estimate and visualize evolutionary conservation in 
macromolecules. Nucleic Acids Res. 44, 1–7 
 
  
BMP-2 binding of vWC domains of Collagen IIA and CCN3 
 14 
FIGURE LEGENDS 
 
FIGURE 1. The tripartite structure of the vWC domains of Col2a and CCN3. A, Domain diagrams of 
Col2a and CCN3 with the two vWC domains coloured in purple and red, respectively. The bars underneath 
the diagrams indicate the parts of the proteins used in this study.  B, Ribbon diagram of the crystal structure 
of Col2a vWC, with insets showing 90° rotated detailed views of each of the three major structural features 
with start and end residues labelled. Disulfide bonds are labelled and shown in yellow, and key π-π aromatic 
residues are labelled and shown in teal. The disulfide connectivity is show schematically at the bottom of 
the panel with the residue numbers of each cysteine underneath the diagram.  C, Comparison of the novel 
crystal structure with the existing NMR ensemble  of Col2a vWC (PDB entry 1U5M, thin grey lines), 
aligned based on the structures of the β-hairpin and SD1. D, Ribbon diagram of the CCN3 vWC with insets 
showing 90° rotated views of each of the three major structural features with the start and end residues 
labelled. Disulfide bonds are labelled and shown in yellow, and key π-π aromatic residues are labelled and 
shown in teal. The disulfide connectivity is show schematically at the bottom of the panel, as in (B). 
 
FIGURE 2. Structural and BMP-2 binding epitope comparisons among vWC domains. A-C, Overlays 
of the Col2a (purple) and CCN3 (red), Col2a (purple) and CV-2 (turquoise, PDB entry 3BK3), and CCN3 
(red) and CV-2 (turquoise) vWCs, respectively, with insets showing 90° rotated views of each of the three 
major structural features. D, Overlay of the three vWC domains, with a zoomed in inset highlighting the 
disulfide bonds that link SD1 and SD2. E, Structure of BMP-2 (grey with semi-transparent surface) in 
complex with vWC domain from CV-1 (turquoise). The insets show overlays of Col2a vWC SD1 and 
CCN3 vWC SD1 with CV-2 vWC1 SD1 bound to BMP-2 (grey). Residues in CV-2 involved in BMP-2 
binding are shown as sticks.  
 
FIGURE 3. Characterisation of the binding of Col2a and CCN3 vWC domains to immobilised BMP-
2 by SPR analysis. A, Kinetic analysis of Col2a vWC binding to BMP-2. BMP-2 was immobilised while 
10 – 250 μM Col2a vWC was flowed over the sensor chip surface. Raw data is shown in light gray with 
fitting curves overlaid in black. Each dissociation and association phase was fit separately to give a kon of 
700 ± 300 M-1s-1, koff of 7x10-3 ± 3x10-3 s-1, and KD (koff/kon) of 11 μM (n=2).  B, Equilibrium binding of 
Col2a vWC to BMP-2. Equilibrium response was plotted as dose dependency of Col2a vWC and fit to give 
a KD of 42 ± 6 μM (n=2). Raw traces are shown as inset. C, Binding of 40 μM Col2a vWC  and CCN3 to 
BMP-2 are shown as indicated in the graph. 
 
FIGURE 4. Mutational analysis of the BMP-2 binding epitope of Col2a vWC. A, Ribbon diagram of 
the Col2a vWC crystal structure showing surface exposed hydrophobic residues selected for mutagenesis 
in site I and II. B-G, binding of Col2a vWC variants to immobilised BMP by SPR analysis. B, SPR 
sensorgrams of 40 μM wild-type (black) and mutants (coloured as in A) of Col2a vWC binding to BMP-2. 
C-G, SPR sensorgrams of increasing concentrations of Col2a vWC variants (coloured as in A and B), 
ranging from 10 nM to 50 μM sequentially injected at the time points indicated by arrows. 
 
FIGURE 5. Conservation of Col2a vWC structural and binding motifs. A, Conservation of amino acid 
residues of Col2a among species is shown pictorially using the ConSurf server (http://consurf.tau.ac.il/) 
(65). Residues selected for our mutational analysis are labelled. Full sequence alignments are shown in 
Figure S7. B, Sequence alignment of vWC SD1s known to bind BMP-2. Col2a (human, Uniprot P02458), 
CV-2 (zebrafish, Q5D734), Chordin (mouse, Q9Z0E2) and CHL2 (mouse, Q8VEA6) were aligned using 
Clustal Omega. Conserved cysteines are highlighted in yellow, and conserved π-π aromatic residues in teal. 
Residues involved in Col2a binding to BMP-2 identified in this study are highlighted in purple. Residues 
previously shown to be involved in vWC binding to BMP-2 are highlighted in pink (18, 22). 
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Table 1. X-ray data collection and refinement statistics. 
 
 Col2a vWC CCN3 vWC CCN3 vWC 
V105M/R128M 
PDB code 5NIR n/a 5NB8 n/a 
Data collection     
Temperature (K) 100 100 100 100 
Beamline DLS I24 DLS I02 DLS I04-1 ESRF BM14 
Wavelength (Å) 0.9686 1.9000 0.9173 0.9793 
Space group P212121 P212121 P1 C2 
Cell dimensions     
    a, b, c (Å) 31.9, 60.2, 86.4 30.1, 59.6, 86.6 38.4, 43.1, 72.3 141.7, 43.4, 38.0 
    α, β, γ (°)  90.0, 90.0, 90.0 90.0, 90.0, 90.0 75.3, 2.0,  89.9 90.0, 98.0, 90.0 
Resolution (Å) 49.37-1.74 
(1.75-1.74) 
59.58-1.84 
(1.85-1.84) 
28.58-2.10  
(2.20-2.10) 
19.01-2.43  
(2.59-2.43) 
Rmergeb 0.042 (0.709) 0.053 (0.560) 0.083 (0.596) 0.068 (0.269) 
<I> / σ<I> 22.7 (2.2) 24.8 (2.2) 10.94 (2.60) 12.04 (4.35) 
Number of reflections 112750 144119 130125 65573 
CC ½  1.00 (0.898) 0.999 (0.886) 0.998 (0.864) 0.997 (0.936) 
Unique reflections 17667 12829 25475 16452 
Multiplicity 6.4 (5.9) 11.2 (6.7) 5.1 (4.7) 4.0 (4.0) 
Completeness (%) 100.0 (100.0) 90.8 (37.2) 98.1 (95.3) 97.2 (96.3) 
     
Refinement     
Resolution (Å) 49.37-1.74 (1.84-1.74)  28.58-2.10 (2.18-2.10)  
No. reflections/free 17616 / 894  25446 / 1298  
Rwork / Rfree 
 
0.210 / 0.231  
(0.222 / 0.257) 
 0.189 / 0.216   
(0.253 / 0.302) 
 
No. atoms     
    Protein 1010  2149                       
    Ligand/ion 207  31  
    Water 16  155  
B-factors(Å2)     
    Protein 35.3  49.8  
    Ligand/ion 48.8  92.7  
    Water 47.2  50.5  
R.m.s. deviations     
    Bond lengths (Å) 0.01  0.007                        
    Bond angles (°) 1.18  0.872                      
Values in parentheses are for the highest-resolution shell. 
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Table 2. BMP-2 binding affinities of full-length and/or vWC domains of Col2a, CV-2, Chordin, and 
CHL2.  
 
 Col2a CV-2 Chordin CHL2 
 vWC Full vWC1 Full vWC1 vWC3 vWC4 Full vWC1 vWC3 
KD (nM) 
42000 22(21) 22(21) 20(21) 150(21) 900(21) 50000(21) 10(21) 2200(21) 300(21) 
  20(18)  900(22) 1050(22)   1000(22) 300(22) 
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Figure 1.  
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Figure 2. 
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Figure 3. 
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Figure 4. 
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Figure 5. 
 
 
 
 
 
 
 
